Rally Update:Energy and metals lead the way

As of this writing two hours before the Friday close crude was above $63 up 3%. Since this rally began last week energy stocks have moved up in lockstep. Better than expected housing starts today have boosted the energy complex with volatile nat gas stocks such as KWK...

Rayno 2009 Biotechnology Portfolio-Mid Year Update

The Rayno Biopharm Portfolio is flat YTD. This compares to the broad-based ETF IBB which also flat YTD and the XBI which is down 5% YTD. Biotech in 2009 has significantly lagged the NASDAQ which is up 11%, however the S&P 500 is down 2.7% YTD. The Rayno portfolio...

H1N1 Flu Pandemic is here but Moderate in Severity

Drug Stocks rally on Flu News On Thursday June 11,the WHO raised its alert on swine flu (H1N1) to the Phase 6 pandemic level calling further spread of the virus inevitable. The Director- General of WHO Dr. Margaret Chan said, “Globally we have good reason to...

Perfect Storm of Financial Distress from BIO

BIOblog for GEN BIO Super Session Weathering the Perfect Storm of Financial Distress Rod Raynovich 5/20/09 At the end of this session someone in the audience asked, ”You described the Perfect Storm but didn’t tell us how to weather it?” Vaughn Kailian answered, ”Wrap...

Update on Biomarkers From BIO Conf

BIOblog for GEN Update on Biomarkers Rod Raynovich 5/19/09 In the October 1 issue of GEN I wrote a review of the impact of genomics in diagnostics and the potential of “companion diagnostics” or the synergy of diagnostics with therapeutics. Biomarkers will continue to...

Swine Flu fear boost Biotechs

The U.S. Government declared an emergency Sunday and released 25% of Relenza and Tamiflu antiviral treatment courses for use by healthcare providers should cases escalate. Tamiflu was developed by Gilead and manufactured and sold by Roche; Relenza is made by...

Q1 Biotechnology Update

The March rally improved the performance of the Life Science sector in Q1 but trailed gains in the technology sector. The S&P Healthcare Index lost 8.5% in Q1 compared to the S&P 500 loss of 11.7%. The S&P Technology Sector gained about 2% in 2009. The...

Big Rally in Biopharm coming off technical bottoms

Biotech and large cap pharmaceutical stocks rallied today overcoming fears of the Obama administration healthcare initiatives that created a bearish pall on the industry. The mood is reminiscent of Hilary care in the early nineties (see my article in Genetic...

Blockbuster mergers fail to lift Biotech stocks

Roche boosted its price to $95 to buy Genentech as expected and Merck will buy Schering Plough for a cash and stock deal valued at $41B including $10.50 in cash. M&A was one of the themes expected to support biotech stocks in 2009 and smaller deals have been...

JPMorgan Healthcare Conference#2

JPMorgan Healthcare Conference Notes from January 13-14, 2009 Rod Raynovich Healthcare –“The Big Idea” for 2009? As the Conference winds down today the buzz has remained positive despite being buffeted this week by a nasty stock market, negative economic indicators...

Pin It on Pinterest